KR102120883B1 - 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 - Google Patents

인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 Download PDF

Info

Publication number
KR102120883B1
KR102120883B1 KR1020147030684A KR20147030684A KR102120883B1 KR 102120883 B1 KR102120883 B1 KR 102120883B1 KR 1020147030684 A KR1020147030684 A KR 1020147030684A KR 20147030684 A KR20147030684 A KR 20147030684A KR 102120883 B1 KR102120883 B1 KR 102120883B1
Authority
KR
South Korea
Prior art keywords
cancer
degrees
polymorph
compound
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147030684A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002730A (ko
Inventor
케빈 웨인 쿤츠
관춘 황
형욱 최
크리스틴 샌더스
스티븐 마티유
아라니 찬다
프랭크 팡
Original Assignee
에피자임, 인코포레이티드
에자이 알앤드디 매니지먼트 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에피자임, 인코포레이티드, 에자이 알앤드디 매니지먼트 가부시키가이샤 filed Critical 에피자임, 인코포레이티드
Priority to KR1020207015664A priority Critical patent/KR102438340B1/ko
Publication of KR20150002730A publication Critical patent/KR20150002730A/ko
Application granted granted Critical
Publication of KR102120883B1 publication Critical patent/KR102120883B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
KR1020147030684A 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태 Active KR102120883B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207015664A KR102438340B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624215P 2012-04-13 2012-04-13
US61/624,215 2012-04-13
PCT/US2013/036193 WO2013155317A1 (en) 2012-04-13 2013-04-11 Salt form of a human hi stone methyltransf erase ezh2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207015664A Division KR102438340B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Publications (2)

Publication Number Publication Date
KR20150002730A KR20150002730A (ko) 2015-01-07
KR102120883B1 true KR102120883B1 (ko) 2020-06-09

Family

ID=49328166

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020147030684A Active KR102120883B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020207015664A Active KR102438340B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020227029511A Active KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020247041285A Pending KR20250005505A (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020207015664A Active KR102438340B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020227029511A Active KR102744039B1 (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR1020247041285A Pending KR20250005505A (ko) 2012-04-13 2013-04-11 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Country Status (26)

Country Link
US (7) US9394283B2 (https=)
EP (4) EP3184523B1 (https=)
JP (3) JP6255382B2 (https=)
KR (4) KR102120883B1 (https=)
CN (2) CN104603130B (https=)
AU (2) AU2013245878B2 (https=)
BR (1) BR112014025508B1 (https=)
CA (1) CA2870005C (https=)
CY (2) CY1119383T1 (https=)
DK (3) DK3184523T3 (https=)
ES (3) ES2745016T3 (https=)
HR (2) HRP20170295T1 (https=)
HU (3) HUE060881T2 (https=)
IL (4) IL282732B2 (https=)
IN (1) IN2014DN09068A (https=)
LT (2) LT2836491T (https=)
MX (2) MX384641B (https=)
NZ (1) NZ700761A (https=)
PL (3) PL3628670T3 (https=)
PT (3) PT3184523T (https=)
RS (2) RS55690B1 (https=)
RU (1) RU2658911C2 (https=)
SG (3) SG10201608577RA (https=)
SI (2) SI2836491T1 (https=)
SM (2) SMT201900501T1 (https=)
WO (1) WO2013155317A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220123339A (ko) * 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
PE20150887A1 (es) 2012-10-15 2015-06-04 Epizyme Inc Compuestos de benceno sustituidos
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014177982A1 (en) 2013-04-30 2014-11-06 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of zeste homolog 2 inhibitors
AU2014288839B2 (en) 2013-07-10 2017-02-02 Glaxosmithkline Intellectual Property (No.2) Limited Enhancer of Zeste Homolog 2 inhibitors
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태
EP3057594A4 (en) * 2013-10-18 2017-06-07 Epizyme, Inc. Method of treating cancer
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
CA2931263A1 (en) 2013-12-06 2015-06-11 Epizyme, Inc. Combination therapy for treating cancer
IL285201B2 (en) 2014-06-17 2024-05-01 Epizyme Inc EZH2 inhibitors for the treatment of lymphoma
PL3157928T3 (pl) 2014-06-20 2019-07-31 Constellation Pharmaceuticals, Inc. Krystaliczne postacie 2-((4S)-6-(4-chlorofenylo)-1-metylo-4H-benzo[ c]izoksazolo-[4,5-e]azepin-4-ylo)acetamidu
IL310279A (en) 2014-10-16 2024-03-01 Epizyme Inc Method for treating cancer
HUE062159T2 (hu) * 2014-11-17 2023-10-28 Epizyme Inc Módszer a rák kezelésére N-((4,6-dimetil-2-oxo-l,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H -pirán-4-il)amino)-4-metil-4'-(morfolinmetil)-[1,1'-bifenil]-3-karboxamiddal
AR102767A1 (es) 2014-12-05 2017-03-22 Lilly Co Eli Inhibidores de ezh2
CN108135908A (zh) 2015-04-20 2018-06-08 Epizyme股份有限公司 用于治疗癌症的组合疗法
EP3307713A4 (en) 2015-06-10 2019-01-23 Epizyme, Inc. EZH2 INHIBITOR FOR THE TREATMENT OF LYMPHOMA
KR20180042356A (ko) 2015-08-24 2018-04-25 에피자임, 인코포레이티드 암 치료 방법
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
WO2017132518A1 (en) 2016-01-29 2017-08-03 Epizyme, Inc. Combination therapy for treating cancer
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
EP3471830A4 (en) 2016-06-17 2020-02-26 Epizyme Inc EZH2 INHIBITORS TO TREAT CANCER
CN109843870A (zh) 2016-10-19 2019-06-04 星座制药公司 Ezh2抑制剂的合成
WO2018137639A1 (zh) * 2017-01-25 2018-08-02 恩瑞生物医药科技（上海）有限公司 一种组蛋白甲基转移酶ezh2抑制剂、其制备方法及其医药用途
US11642346B2 (en) 2017-03-31 2023-05-09 Epizyme, Inc. Combination therapy for treating cancer
EP3630080A4 (en) 2017-06-02 2021-03-10 Epizyme, Inc. USE OF EZH2 INHIBITORS TO TREAT CANCER
WO2019050924A1 (en) 2017-09-05 2019-03-14 Epizyme, Inc. POLY THERAPY FOR THE TREATMENT OF CANCER
HRP20240793T1 (hr) 2018-04-18 2024-09-13 Constellation Pharmaceuticals, Inc. Modulatori enzima koji modificiraju metil, njihovi pripravci i upotreba
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
LT4003532T (lt) 2019-07-24 2024-11-11 Constellation Pharmaceuticals, Inc. 7-chlor-2- (4-(3-metoksiazetidin-1-il)cikloheksil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-okso-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioksol-5-karboksamido kristalinės formos
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물
WO2022208552A1 (en) * 2021-03-31 2022-10-06 Msn Laboratories Private Limited, R&D Center Crystalline forms of [1,1'-Biphenyl]-3-carboxamide, N-[(1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl]-5-[ethyl(tetrahydro-2H-pyran-4-yl)amino]-4-methyl-4'-(4-morpholinylmethyl)-, hydrobromide (1:1) and process for its preparation thereof
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0733729A (ja) 1993-07-26 1995-02-03 Kirin Brewery Co Ltd Ｎ−シアノ−ｎ′−置換−アリールカルボキシイミダミド化合物の製造法
US5716993A (en) 1993-12-27 1998-02-10 Eisai Co., Ltd. Anthranilic acid derivatives
DE19516776A1 (de) 1995-05-10 1996-11-14 Boehringer Ingelheim Int Chromatin-Regulatorgene
US5741819A (en) 1995-06-07 1998-04-21 3-Dimensional Pharmaceuticals, Inc. Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors
JP3906935B2 (ja) 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
EP1117635A1 (en) 1998-09-30 2001-07-25 The Procter & Gamble Company 2-substituted ketoamides
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
KR100828982B1 (ko) 2000-12-28 2008-05-14 시오노기세이야쿠가부시키가이샤 칸나비노이드 2형 수용체 친화 작용을 갖는 피리돈 유도체
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
ATE447971T1 (de) 2002-02-19 2009-11-15 Shionogi & Co Antipruriginosa
TW200306155A (en) 2002-03-19 2003-11-16 Du Pont Benzamides and advantageous compositions thereof for use as fungicides
US7442685B2 (en) 2003-06-13 2008-10-28 The University Of North Carolina At Chapel Hill DOT1 histone methyltransferases as a target for identifying therapeutic agents for leukemia
WO2005095386A1 (en) 2004-03-30 2005-10-13 Chiron Corporation Substituted thiophene derivatives as anti-cancer agents
EP1765994B1 (en) 2004-06-01 2009-11-18 The University of North Carolina at Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
US7923219B2 (en) 2005-06-02 2011-04-12 The University Of North Carolina At Chapel Hill Ubiquitin E3 ligase
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
DK1940821T3 (da) 2005-10-19 2013-06-10 Gruenenthal Gmbh Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler.
KR20080057296A (ko) 2005-10-21 2008-06-24 머크 앤드 캄파니 인코포레이티드 칼륨 채널 억제제
WO2007053480A2 (en) 2005-10-28 2007-05-10 The University Of North Carolina At Chapel Hill Protein demethylases comprising a jmjc domain
EP1966141A1 (en) 2005-12-14 2008-09-10 Brystol-Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
EP2730661A1 (en) 2006-01-20 2014-05-14 The University of North Carolina at Chapel Hill Diagnostic and therapeutic targets for leukemia
KR20080110905A (ko) 2006-05-15 2008-12-19 아이알엠 엘엘씨 테레프탈라메이트 화합물 및 조성물, 및 ｈｉｖ 인테그라제억제제로서의 그들의 용도
US20070287706A1 (en) 2006-05-18 2007-12-13 Dickson John K Jr Certain substituted quinolones, compositions, and uses thereof
US8022246B2 (en) 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
MX2009008531A (es) 2007-02-16 2009-08-26 Amgen Inc Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met.
EP2137158A4 (en) 2007-02-28 2012-04-18 Methylgene Inc LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS)
WO2008113006A1 (en) 2007-03-14 2008-09-18 Xenon Pharmaceuticals Inc. Methods of using quinolinone compounds in treating sodium channel-mediated diseases or conditions
DE102007017884A1 (de) 2007-04-13 2008-10-16 Grünethal GmbH Neue Vanilloid-Rezeptor Liganden und ihre Verwendung zur Herstellung von Arzneimitteln
WO2009006577A2 (en) 2007-07-03 2009-01-08 The Regents Of The University Of Michigan Compositions and methods for inhibiting ezh2
DE102007047737A1 (de) * 2007-10-05 2009-04-30 Merck Patent Gmbh Piperidin- und Piperazinderivate
JP2011502148A (ja) 2007-10-31 2011-01-20 メルク・シャープ・エンド・ドーム・コーポレイション 疼痛の治療用としてのｐ２ｘ３受容体アンタゴニスト
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
WO2009124137A2 (en) 2008-04-01 2009-10-08 Mount Sinai School Of Medicine Of New York University Method of suppressing gene transcription through histone lysine methylation
US20100113415A1 (en) 2008-05-29 2010-05-06 Rajapakse Hemaka A Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer
US8299093B2 (en) 2008-08-08 2012-10-30 New York Blood Center, Inc. Small molecule inhibitors of retroviral assembly and maturation
FR2934995B1 (fr) 2008-08-14 2010-08-27 Sanofi Aventis Composes d'azetidines polysubstitues, leur preparation et leur application en therapeutique
JP2012522013A (ja) 2009-03-27 2012-09-20 ザ ユーエービー リサーチ ファウンデーション 調節ｉｒｅｓ媒介翻訳
WO2011011366A2 (en) 2009-07-20 2011-01-27 Constellation Pharmaceuticals Agents for stimulating activity of methyl modifying enzymes and methods of use thereof
CA2784899A1 (en) 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
WO2012005805A1 (en) * 2010-05-07 2012-01-12 Glaxosmithkline Llc Azaindazoles
JP5864546B2 (ja) * 2010-05-07 2016-02-17 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ インダゾール
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
BR112013005806B1 (pt) 2010-09-10 2022-05-10 Epizyme, Inc Métodos para detectar se um indivíduo é um candidato para o tratamento com ou responsivo a um inibidor de ezh2 e usos terapêuticos do dito inibidor de ezh2
US20130310379A1 (en) 2010-11-19 2013-11-21 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
EP2646020B1 (en) 2010-12-01 2016-09-21 Glaxosmithkline LLC Indoles
US9145438B2 (en) 2010-12-03 2015-09-29 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
WO2012118812A2 (en) 2011-02-28 2012-09-07 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3363B1 (ar) 2011-04-13 2019-03-13 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
RU2704445C2 (ru) 2012-03-12 2019-10-28 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
SG10201608579UA (en) 2012-04-13 2016-12-29 Epizyme Inc Combination therapy for treating cancer
US9394283B2 (en) * 2012-04-13 2016-07-19 Epizyme, Inc. Salt form of a human histone methyltransferase EZH2 inhibitor
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
CA2887243C (en) 2012-10-15 2024-04-09 Epizyme, Inc. Methods of treating cancer
KR102142177B1 (ko) 2013-10-16 2020-08-07 에피자임, 인코포레이티드 Ezh2 억제용 하이드로클로라이드 염 형태

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011140324A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indoles

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220123339A (ko) * 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
KR102744039B1 (ko) * 2012-04-13 2024-12-17 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태

Also Published As

Publication number Publication date
NZ700761A (en) 2016-09-30
IN2014DN09068A (https=) 2015-05-22
LT2836491T (lt) 2017-03-27
JP2018199740A (ja) 2018-12-20
IL296199A (en) 2022-11-01
PT2836491T (pt) 2017-02-08
DK2836491T3 (en) 2017-03-06
CY1119383T1 (el) 2018-02-14
IL235045B (en) 2019-05-30
IL282732B (en) 2022-12-01
EP3184523B1 (en) 2019-06-19
JP2018002742A (ja) 2018-01-11
WO2013155317A1 (en) 2013-10-17
IL296199B1 (en) 2024-08-01
LT3184523T (lt) 2020-02-10
ES2617379T3 (es) 2017-06-16
IL266165B (en) 2021-06-30
US20230140327A1 (en) 2023-05-04
HUE031976T2 (en) 2017-08-28
MX2014012380A (es) 2015-07-23
MX362339B (es) 2019-01-11
BR112014025508B1 (pt) 2020-11-17
CA2870005A1 (en) 2013-10-17
US20250268905A1 (en) 2025-08-28
CA2870005C (en) 2021-06-22
RU2014145544A (ru) 2016-06-10
CN104603130B (zh) 2018-04-27
KR102438340B1 (ko) 2022-08-30
EP2836491B1 (en) 2016-12-07
AU2013245878A1 (en) 2014-10-30
US20210137936A1 (en) 2021-05-13
PT3184523T (pt) 2019-09-26
CY1122883T1 (el) 2022-03-24
DK3184523T3 (da) 2019-08-19
IL296199B2 (en) 2024-12-01
IL282732B2 (en) 2023-04-01
IL235045A0 (en) 2014-12-31
IL282732A (en) 2021-06-30
SG10201912109QA (en) 2020-02-27
US10821113B2 (en) 2020-11-03
MX384641B (es) 2025-03-14
EP3628670A1 (en) 2020-04-01
KR102744039B1 (ko) 2024-12-17
CN108358899B (zh) 2021-07-27
KR20150002730A (ko) 2015-01-07
US10245269B2 (en) 2019-04-02
CN104603130A (zh) 2015-05-06
HRP20191653T1 (hr) 2020-02-21
DK3628670T3 (da) 2022-12-05
US20180243316A1 (en) 2018-08-30
AU2018200168B2 (en) 2019-08-29
ES2931316T3 (es) 2022-12-28
AU2018200168A1 (en) 2018-02-01
ES2745016T3 (es) 2020-02-27
JP6634058B2 (ja) 2020-01-22
EP3184523A1 (en) 2017-06-28
PL3628670T3 (pl) 2023-02-20
PT3628670T (pt) 2022-12-02
HRP20170295T1 (hr) 2017-04-21
JP6255382B2 (ja) 2017-12-27
EP4190777A1 (en) 2023-06-07
KR20250005505A (ko) 2025-01-09
SMT201900501T1 (it) 2019-11-13
CN108358899A (zh) 2018-08-03
HUE045353T2 (hu) 2019-12-30
US20150065503A1 (en) 2015-03-05
EP3628670B1 (en) 2022-10-12
US12251386B2 (en) 2025-03-18
HUE060881T2 (hu) 2023-04-28
KR20200066380A (ko) 2020-06-09
SI2836491T1 (sl) 2017-06-30
SG11201406468YA (en) 2015-01-29
RS59392B1 (sr) 2019-11-29
US9394283B2 (en) 2016-07-19
RS55690B1 (sr) 2017-07-31
JP2015512942A (ja) 2015-04-30
SMT201700132T1 (it) 2017-05-08
US20170143729A1 (en) 2017-05-25
RU2658911C2 (ru) 2018-06-26
SG10201608577RA (en) 2016-12-29
SI3184523T1 (sl) 2020-04-30
PL3184523T3 (pl) 2019-12-31
US11491163B2 (en) 2022-11-08
AU2013245878B2 (en) 2017-10-12
EP2836491A4 (en) 2015-09-16
EP2836491A1 (en) 2015-02-18
IL266165A (en) 2019-06-30
US20190269692A1 (en) 2019-09-05
US9872862B2 (en) 2018-01-23
PL2836491T3 (pl) 2017-08-31
KR20220123339A (ko) 2022-09-06

Similar Documents

Publication Publication Date Title
KR102120883B1 (ko) 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
HK40087682A (en) Hbr salt form for ezh2 inhibition
HK40026825B (en) Salt form for ezh2 inhibition
HK40026825A (en) Salt form for ezh2 inhibition

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6